# Evaluate the Concordance Between PET Imaging of [18F]-APN-1607 Injection and Postmortem Brain Tissue Tau Pathology in Individuals With HV and MCI or AD.

> **NCT07752784** · PHASE3 · RECRUITING · sponsor: **JYAMS PET Research & Development Limited** · enrollment: 12 (estimated)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** [18F]-APN-1607

## Key facts

- **NCT ID:** NCT07752784
- **Lead sponsor:** JYAMS PET Research & Development Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-08-15
- **Primary completion:** 2027-04-30
- **Final completion:** 2027-08-15
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2026-08-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07752784

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07752784, "Evaluate the Concordance Between PET Imaging of [18F]-APN-1607 Injection and Postmortem Brain Tissue Tau Pathology in Individuals With HV and MCI or AD.". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07752784. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*